[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632275":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":19,"collaborators":21,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":31,"acronym":32,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":7,"maxAge":7,"enrollmentInfo":35,"targetDuration":7,"studyType":38,"phases":7,"briefSummary":39,"conditions":40,"keywords":7,"overallStatus":45,"whyStopped":7,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":7},{"fullName":5,"class":6},"Centre Hospitalier de Bligny","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","longitudinal blood sampling and standardized neurological evaluation over 6 months","Prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Jean-Baptiste Méric, MD","CONTACT","33+686961024","jb.meric@chbligny.fr",{"type":20,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[22,24],{"name":23,"class":6},"Hopital Forcilles",{"name":25,"class":26},"AgenT","UNKNOWN","100632275","prospective-exploratory-study-of-a-multiomic-blood-biomarker-panel-to-predict-chemotherapy-induced-peripheral-neuropathy-cipn-100632275",false,"NCT07511569","Prospective Exploratory Study of a Multiomic Blood Biomarker Panel to Predict Chemotherapy-Induced Peripheral Neuropathy (CIPN)","PRECISE1","Inclusion Criteria:\n\n* Patients who have received detailed information about the study and have signed, with the investigator, a consent form to participate in the study\n* Patients being treated for cancer at any stage of the disease and scheduled to receive chemotherapy including one (and only one) of the following molecules: paclitaxel, docetaxel, or oxaliplatin, for a planned duration of 9 weeks or more\n* Age \\> 18 years\n* Life expectancy \\> 3 months\n* Patient affiliated with or entitled to social security\n\nExclusion Criteria:\n\n* Patients already suffering from neuropathy or chronic neurogenic pain\n* Patients with type 1 or type 2 diabetes (for more than 10 years for type 2 diabetes)\n* Patients who have already received neurotoxic cancer treatment including those in clinical trials\n* Patients receiving two of the study molecules simultaneously (only one study molecule is permitted, including in combination chemotherapy but that does not include another neurotoxic molecule)\n* Patients receiving immunotherapy","ALL",{"count":36,"type":37},192,"ESTIMATED","OBSERVATIONAL","The goal of this prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months is to identify biomarkers to predict the overall occurrence of chronic chemotherapy-induced peripheral neuropathy (CIPN, any grade), in each of two treatment subgroups (taxanes and oxaliplatin). It involves integration of clinical data and plasma multiomic biomarkers (proteomic + metabolomic panel) analyzed via supervised machine learning to identify predictive features of CIPN.",[41,42,43,44],"Chemotherapy Induced Neuropathic Pain","Neuropathy Toxic","Taxane-induced Peripheral Neuropathy","Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients","NOT_YET_RECRUITING","2026-04-07",{"date":48,"type":49},"2026-04-13","ACTUAL",{"date":51,"type":37},"2027-01-04",{"date":53,"type":37},"2029-06-04",{"name":5,"class":6}]